{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:39Z","timestamp":1791474699497,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["DFG PA930\/12"],"award-info":[{"award-number":["DFG PA930\/12"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006590","name":"Ministerium f\u00fcr Wissenschaft und Wirtschaft, Land Sachsen-Anhalt","doi-asserted-by":"publisher","award":["EFRE"],"award-info":[{"award-number":["EFRE"]}],"id":[{"id":"10.13039\/501100006590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006590","name":"Ministerium f\u00fcr Wissenschaft und Wirtschaft, Land Sachsen-Anhalt","doi-asserted-by":"publisher","award":["ZS\/2016\/05\/78617"],"award-info":[{"award-number":["ZS\/2016\/05\/78617"]}],"id":[{"id":"10.13039\/501100006590","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leibniz-Gemeinschaft","award":["SAW-2015-IPB-2"],"award-info":[{"award-number":["SAW-2015-IPB-2"]}]},{"DOI":"10.13039\/501100013263","name":"Nasjonalforeningen for Folkehelsen","doi-asserted-by":"publisher","award":["16154"],"award-info":[{"award-number":["16154"]}],"id":[{"id":"10.13039\/501100013263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2016062"],"award-info":[{"award-number":["2016062"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2019054"],"award-info":[{"award-number":["2019054"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2019055"],"award-info":[{"award-number":["2019055"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Norsk forskningsr\u00e5det","award":["251290 FRIMEDIO"],"award-info":[{"award-number":["251290 FRIMEDIO"]}]},{"name":"Norsk forskningsr\u00e5det","award":["260786 PROP-AD"],"award-info":[{"award-number":["260786 PROP-AD"]}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["643417 (PROP-AD)"],"award-info":[{"award-number":["643417 (PROP-AD)"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["643417 (JPco-fuND)"],"award-info":[{"award-number":["643417 (JPco-fuND)"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40268-020-00316-1","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T20:09:42Z","timestamp":1595362182000},"page":"197-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-8899","authenticated-orcid":false,"given":"Pablo","family":"Bascu\u00f1ana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"M\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Brackhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Pahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"issue":"5566","key":"316_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.1070238","volume":"296","author":"S Mandala","year":"2002","unstructured":"Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346\u20139. https:\/\/doi.org\/10.1126\/science.1070238.","journal-title":"Science"},{"issue":"6972","key":"316_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355\u201360. https:\/\/doi.org\/10.1038\/nature02284.","journal-title":"Nature"},{"issue":"10","key":"316_CR3","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","volume":"160","author":"K Chiba","year":"1998","unstructured":"Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160(10):5037\u201344.","journal-title":"J Immunol."},{"issue":"1","key":"316_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84\u2013105. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.04.006.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"316_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","volume":"28","author":"TH Pham","year":"2008","unstructured":"Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008;28(1):122\u201333. https:\/\/doi.org\/10.1016\/j.immuni.2007.11.017.","journal-title":"Immunity"},{"issue":"6","key":"316_CR6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1523\/jneurosci.4645-04.2005","volume":"25","author":"C Jaillard","year":"2005","unstructured":"Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, et al. Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459\u201369. https:\/\/doi.org\/10.1523\/jneurosci.4645-04.2005.","journal-title":"J Neurosci"},{"key":"316_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1742-2094-9-133","volume":"9","author":"R van Doorn","year":"2012","unstructured":"van Doorn R, Lopes Pinheiro MA, Kooij G, Lakeman K, van het Hof B, van der Pol SM, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflamm. 2012;9:133. https:\/\/doi.org\/10.1186\/1742-2094-9-133.","journal-title":"J Neuroinflamm."},{"issue":"1","key":"316_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ana.21227","volume":"63","author":"VE Miron","year":"2008","unstructured":"Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008;63(1):61\u201371. https:\/\/doi.org\/10.1002\/ana.21227.","journal-title":"Ann Neurol"},{"issue":"8","key":"316_CR9","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s12035-018-1448-3","volume":"56","author":"K Czubowicz","year":"2019","unstructured":"Czubowicz K, Jesko H, Wencel P, Lukiw WJ, Strosznajder RP. The role of ceramide and sphingosine-1-phosphate in Alzheimer\u2019s disease and other neurodegenerative disorders. Mol Neurobiol. 2019;56(8):5436\u201355. https:\/\/doi.org\/10.1007\/s12035-018-1448-3.","journal-title":"Mol Neurobiol"},{"key":"316_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34\u201349. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.11.001.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"316_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s0952-7915(02)00374-6","volume":"14","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 2002;14(5):569\u201375. https:\/\/doi.org\/10.1016\/s0952-7915(02)00374-6.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"316_CR12","first-page":"439","volume":"2","author":"H Kataoka","year":"2005","unstructured":"Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005;2(6):439\u201348.","journal-title":"Cell Mol Immunol"},{"issue":"1\u20132","key":"316_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2004.04.015","volume":"153","author":"M Webb","year":"2004","unstructured":"Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004;153(1\u20132):108\u201321. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.04.015.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"316_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/nejmoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401. https:\/\/doi.org\/10.1056\/nejmoa0909494.","journal-title":"N Engl J Med."},{"issue":"5","key":"316_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/nejmoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315. https:\/\/doi.org\/10.1056\/nejmoa0907839.","journal-title":"N Engl J Med."},{"issue":"4","key":"316_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1476-5381.2011.01579.x","volume":"165","author":"S Rossi","year":"2012","unstructured":"Rossi S, Lo Giudice T, De Chiara V, Musella A, Studer V, Motta C, et al. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol. 2012;165(4):861\u20139. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01579.x.","journal-title":"Br J Pharmacol"},{"key":"316_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jneuroim.2018.02.016","volume":"318","author":"PA Smith","year":"2018","unstructured":"Smith PA, Schmid C, Zurbruegg S, Jivkov M, Doelemeyer A, Theil D, et al. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis. J Neuroimmunol. 2018;318:103\u201313. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.02.016.","journal-title":"J Neuroimmunol"},{"key":"316_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nbd.2015.01.006","volume":"76","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang ZG, Li Y, Ding X, Shang X, Lu M, et al. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis. 2015;76:57\u201366. https:\/\/doi.org\/10.1016\/j.nbd.2015.01.006.","journal-title":"Neurobiol Dis"},{"issue":"1\u20132","key":"316_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","volume":"328","author":"A Groves","year":"2013","unstructured":"Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1\u20132):9\u201318. https:\/\/doi.org\/10.1016\/j.jns.2013.02.011.","journal-title":"J Neurol Sci"},{"issue":"1","key":"316_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12883-020-01645-z","volume":"20","author":"C Albert","year":"2020","unstructured":"Albert C, Mikolajczak J, Liekfeld A, Piper SK, Scheel M, Zimmermann HG, et al. Fingolimod after a first unilateral episode of acute optic neuritis (MOVING)\u2014preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. BMC Neurol. 2020;20(1):75. https:\/\/doi.org\/10.1186\/s12883-020-01645-z.","journal-title":"BMC Neurol."},{"issue":"2","key":"316_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/wno.0b013e31828ea2fc","volume":"33","author":"X An","year":"2013","unstructured":"An X, Kezuka T, Usui Y, Matsunaga Y, Matsuda R, Yamakawa N, et al. Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod. J Neuroophthalmol. 2013;33(2):143\u20138. https:\/\/doi.org\/10.1097\/wno.0b013e31828ea2fc.","journal-title":"J Neuroophthalmol"},{"issue":"15","key":"316_CR22","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1523\/jneurosci.2346-19.2020","volume":"40","author":"S Bechet","year":"2020","unstructured":"Bechet S, O\u2019Sullivan SA, Yssel J, Fagan SG, Dev KK. Fingolimod rescues demyelination in a mouse model of Krabbe\u2019s disease. J Neurosci. 2020;40(15):3104\u201318. https:\/\/doi.org\/10.1523\/jneurosci.2346-19.2020.","journal-title":"J Neurosci"},{"issue":"6","key":"316_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/17482968.2010.495158","volume":"11","author":"JD Mitchell","year":"2010","unstructured":"Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)\u2013a 20-year review: can we do better? Amyotroph Lateral Scler. 2010;11(6):537\u201341. https:\/\/doi.org\/10.3109\/17482968.2010.495158.","journal-title":"Amyotroph Lateral Scler."},{"key":"316_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112818","author":"MAJ van den Bos","year":"2019","unstructured":"van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112818.","journal-title":"Int J Mol Sci."},{"issue":"Pt A","key":"316_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.024","volume":"1693","author":"C Lutz","year":"2018","unstructured":"Lutz C. Mouse models of ALS: past, present and future. Brain Res. 2018;1693(Pt A):1\u201310. https:\/\/doi.org\/10.1016\/j.brainres.2018.03.024.","journal-title":"Brain Res"},{"issue":"7","key":"316_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1212\/wnl.57.7.1282","volume":"57","author":"ME Alexianu","year":"2001","unstructured":"Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57(7):1282\u20139. https:\/\/doi.org\/10.1212\/wnl.57.7.1282.","journal-title":"Neurology."},{"key":"316_CR27","doi-asserted-by":"publisher","first-page":"803701","DOI":"10.1155\/2012\/803701","volume":"2012","author":"CA Lewis","year":"2012","unstructured":"Lewis CA, Manning J, Rossi F, Krieger C. The neuroinflammatory response in ALS: the roles of microglia and T cells. Neurol Res Int. 2012;2012:803701. https:\/\/doi.org\/10.1155\/2012\/803701.","journal-title":"Neurol Res Int."},{"issue":"6","key":"316_CR28","first-page":"289","volume":"8","author":"D Troost","year":"1989","unstructured":"Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8(6):289\u201394.","journal-title":"Clin Neuropathol"},{"issue":"4","key":"316_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","volume":"13","author":"RL Potenza","year":"2016","unstructured":"Potenza RL, De Simone R, Armida M, Mazziotti V, Pezzola A, Popoli P, et al. Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2016;13(4):918\u201327. https:\/\/doi.org\/10.1007\/s13311-016-0462-2.","journal-title":"Neurotherapeutics."},{"issue":"6","key":"316_CR30","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mus.25733","volume":"56","author":"JD Berry","year":"2017","unstructured":"Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56(6):1077\u201384. https:\/\/doi.org\/10.1002\/mus.25733.","journal-title":"Muscle Nerve"},{"key":"316_CR31","unstructured":"World Health Organization. AD report 2019. 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed 17 Jun 2019."},{"issue":"44","key":"316_CR32","doi-asserted-by":"publisher","first-page":"29615","DOI":"10.1074\/jbc.r800019200","volume":"283","author":"G Thinakaran","year":"2008","unstructured":"Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283(44):29615\u20139. https:\/\/doi.org\/10.1074\/jbc.r800019200.","journal-title":"J Biol Chem"},{"issue":"2","key":"316_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101\u201312. https:\/\/doi.org\/10.1038\/nrm2101.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Pt A","key":"316_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.nbd.2014.04.001","volume":"72","author":"J Pahnke","year":"2014","unstructured":"Pahnke J, Langer O, Krohn M. Alzheimer\u2019s and ABC transporters\u2013new opportunities for diagnostics and treatment. Neurobiol Dis. 2014;72(Pt A):54\u201360. https:\/\/doi.org\/10.1016\/j.nbd.2014.04.001.","journal-title":"Neurobiol Dis."},{"issue":"7","key":"316_CR35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.neubiorev.2009.05.006","volume":"33","author":"J Pahnke","year":"2009","unstructured":"Pahnke J, Walker LC, Scheffler K, Krohn M. Alzheimer\u2019s disease and blood-brain barrier function\u2014why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev. 2009;33(7):1099\u2013108. https:\/\/doi.org\/10.1016\/j.neubiorev.2009.05.006.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"316_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25(1):59\u201370. https:\/\/doi.org\/10.1111\/ene.13439.","journal-title":"Eur J Neurol"},{"issue":"1","key":"316_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40478-020-00931-8","volume":"8","author":"A Elsherbini","year":"2020","unstructured":"Elsherbini A, Kirov AS, Dinkins MB, Wang G, Qin H, Zhu Z, et al. Association of Abeta with ceramide-enriched astrosomes mediates Abeta neurotoxicity. Acta Neuropathol Commun. 2020;8(1):60. https:\/\/doi.org\/10.1186\/s40478-020-00931-8.","journal-title":"Acta Neuropathol Commun."},{"issue":"6","key":"316_CR38","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s12035-020-01908-3","volume":"57","author":"H Jesko","year":"2020","unstructured":"Jesko H, Wencel PL, Wojtowicz S, Strosznajder J, Lukiw WJ, Strosznajder RP. Fingolimod affects transcription of genes encoding enzymes of ceramide metabolism in animal model of Alzheimer\u2019s disease. Mol Neurobiol. 2020;57(6):2799\u2013811. https:\/\/doi.org\/10.1007\/s12035-020-01908-3.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"316_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond). 2016;16(3):247\u201353. https:\/\/doi.org\/10.7861\/clinmedicine.16-3-247.","journal-title":"Clin Med (Lond)."},{"issue":"4","key":"316_CR40","doi-asserted-by":"publisher","first-page":"e61988","DOI":"10.1371\/journal.pone.0061988","volume":"8","author":"Y Doi","year":"2013","unstructured":"Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, et al. Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One. 2013;8(4):e61988. https:\/\/doi.org\/10.1371\/journal.pone.0061988.","journal-title":"PLoS One"},{"issue":"15","key":"316_CR41","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1039\/c4lc00174e","volume":"14","author":"A Ruiz","year":"2014","unstructured":"Ruiz A, Joshi P, Mastrangelo R, Francolini M, Verderio C, Matteoli M. Testing Abeta toxicity on primary CNS cultures using drug-screening microfluidic chips. Lab Chip. 2014;14(15):2860\u20136. https:\/\/doi.org\/10.1039\/c4lc00174e.","journal-title":"Lab Chip"},{"issue":"5","key":"316_CR42","doi-asserted-by":"publisher","first-page":"e64050","DOI":"10.1371\/journal.pone.0064050","volume":"8","author":"N Takasugi","year":"2013","unstructured":"Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, et al. FTY720\/fingolimod, a sphingosine analogue, reduces amyloid-beta production in neurons. PLoS One. 2013;8(5):e64050. https:\/\/doi.org\/10.1371\/journal.pone.0064050.","journal-title":"PLoS One"},{"issue":"4","key":"316_CR43","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12031-014-0423-3","volume":"54","author":"M Asle-Rousta","year":"2014","unstructured":"Asle-Rousta M, Kolahdooz Z, Dargahi L, Ahmadiani A, Nasoohi S. Prominence of central sphingosine-1-phosphate receptor-1 in attenuating abeta-induced injury by fingolimod. J Mol Neurosci. 2014;54(4):698\u2013703. https:\/\/doi.org\/10.1007\/s12031-014-0423-3.","journal-title":"J Mol Neurosci"},{"key":"316_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbr.2013.06.016","volume":"252","author":"F Hemmati","year":"2013","unstructured":"Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Chik Z, et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer\u2019s disease: comparison with memantine. Behav Brain Res. 2013;252:415\u201321. https:\/\/doi.org\/10.1016\/j.bbr.2013.06.016.","journal-title":"Behav Brain Res"},{"issue":"3","key":"316_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12031-013-9979-6","volume":"50","author":"M Asle-Rousta","year":"2013","unstructured":"Asle-Rousta M, Kolahdooz Z, Oryan S, Ahmadiani A, Dargahi L. FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats. J Mol Neurosci. 2013;50(3):524\u201332. https:\/\/doi.org\/10.1007\/s12031-013-9979-6.","journal-title":"J Mol Neurosci"},{"key":"316_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbr.2014.03.046","volume":"268","author":"K Fukumoto","year":"2014","unstructured":"Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. Behav Brain Res. 2014;268:88\u201393. https:\/\/doi.org\/10.1016\/j.bbr.2014.03.046.","journal-title":"Behav Brain Res"},{"key":"316_CR47","doi-asserted-by":"publisher","first-page":"24939","DOI":"10.1038\/srep24939","volume":"6","author":"N Aytan","year":"2016","unstructured":"Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, et al. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer\u2019s disease. Sci Rep. 2016;6:24939. https:\/\/doi.org\/10.1038\/srep24939.","journal-title":"Sci Rep."},{"issue":"1","key":"316_CR48","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1038\/s41598-019-47287-1","volume":"9","author":"I Carreras","year":"2019","unstructured":"Carreras I, Aytan N, Choi JK, Tognoni CM, Kowall NW, Jenkins BG, et al. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer\u2019s disease. Sci Rep. 2019;9(1):10972. https:\/\/doi.org\/10.1038\/s41598-019-47287-1.","journal-title":"Sci Rep."},{"issue":"4","key":"316_CR49","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s11481-017-9753-6","volume":"12","author":"RM McManus","year":"2017","unstructured":"McManus RM, Finucane OM, Wilk MM, Mills KHG, Lynch MA. FTY720 attenuates infection-induced enhancement of abeta accumulation in APP\/PS1 mice by modulating astrocytic activation. J Neuroimmune Pharmacol. 2017;12(4):670\u201381. https:\/\/doi.org\/10.1007\/s11481-017-9753-6.","journal-title":"J Neuroimmune Pharmacol."},{"issue":"3","key":"316_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-012-1014-4","volume":"124","author":"R van Doorn","year":"2012","unstructured":"van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van het Hof B, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012;124(3):397\u2013410. https:\/\/doi.org\/10.1007\/s00401-012-1014-4.","journal-title":"Acta Neuropathol"},{"key":"316_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lfs.2015.07.017","volume":"137","author":"K Kinoshita","year":"2015","unstructured":"Kinoshita K, Tada Y, Muroi Y, Unno T, Ishii T. Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning. Life Sci. 2015;137:28\u201336. https:\/\/doi.org\/10.1016\/j.lfs.2015.07.017.","journal-title":"Life Sci"},{"issue":"9996","key":"316_CR52","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3.","journal-title":"Lancet"},{"issue":"1","key":"316_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6\u201323. https:\/\/doi.org\/10.1007\/s13311-013-0218-1.","journal-title":"Neurotherapeutics."},{"issue":"2","key":"316_CR54","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","volume":"42","author":"M Ren","year":"2017","unstructured":"Ren M, Han M, Wei X, Guo Y, Shi H, Zhang X, et al. FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models. Neurochem Res. 2017;42(2):686\u201396. https:\/\/doi.org\/10.1007\/s11064-016-2125-4.","journal-title":"Neurochem Res"},{"issue":"1","key":"316_CR55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1096\/fj.201600751r","volume":"31","author":"P Zhao","year":"2017","unstructured":"Zhao P, Yang X, Yang L, Li M, Wood K, Liu Q, et al. Neuroprotective effects of fingolimod in mouse models of Parkinson\u2019s disease. FASEB J. 2017;31(1):172\u20139. https:\/\/doi.org\/10.1096\/fj.201600751r.","journal-title":"FASEB J."},{"issue":"3","key":"316_CR56","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","volume":"14","author":"S Yao","year":"2019","unstructured":"Yao S, Li L, Sun X, Hua J, Zhang K, Hao L, et al. FTY720 inhibits MPP(+)-induced microglial activation by affecting NLRP3 inflammasome activation. J Neuroimmune Pharmacol. 2019;14(3):478\u201392. https:\/\/doi.org\/10.1007\/s11481-019-09843-4.","journal-title":"J Neuroimmune Pharmacol."},{"key":"316_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuropharm.2018.02.023","volume":"135","author":"J Motyl","year":"2018","unstructured":"Motyl J, Przykaza L, Boguszewski PM, Kosson P, Strosznajder JB. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson\u2019s disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology. 2018;135:139\u201350. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.023.","journal-title":"Neuropharmacology"},{"key":"316_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2019.05.029","volume":"411","author":"G Vidal-Martinez","year":"2019","unstructured":"Vidal-Martinez G, Najera K, Miranda JD, Gil-Tommee C, Yang B, Vargas-Medrano J, et al. FTY720 improves behavior, increases brain derived neurotrophic factor levels and reduces alpha-synuclein pathology in parkinsonian GM2\u2009\u00b1\u2009mice. Neuroscience. 2019;411:1\u201310. https:\/\/doi.org\/10.1016\/j.neuroscience.2019.05.029.","journal-title":"Neuroscience"},{"issue":"39","key":"316_CR59","doi-asserted-by":"publisher","first-page":"20811","DOI":"10.1074\/jbc.m116.744029","volume":"291","author":"G Vidal-Martinez","year":"2016","unstructured":"Vidal-Martinez G, Vargas-Medrano J, Gil-Tommee C, Medina D, Garza NT, Yang B, et al. FTY720\/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. J Biol Chem. 2016;291(39):20811\u201321. https:\/\/doi.org\/10.1074\/jbc.m116.744029.","journal-title":"J Biol Chem"},{"issue":"5","key":"316_CR60","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/jnc.14575","volume":"147","author":"D Komnig","year":"2018","unstructured":"Komnig D, Dagli TC, Habib P, Zeyen T, Schulz JB, Falkenburger BH. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson\u2019s disease and does not lead to a sustainable increase of brain-derived neurotrophic factor. J Neurochem. 2018;147(5):678\u201391. https:\/\/doi.org\/10.1111\/jnc.14575.","journal-title":"J Neurochem"},{"issue":"4","key":"316_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u201382. https:\/\/doi.org\/10.1111\/epi.12550.","journal-title":"Epilepsia."},{"issue":"6","key":"316_CR62","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1528-1167.2011.03041.x","volume":"52","author":"SD Shorvon","year":"2011","unstructured":"Shorvon SD. The etiologic classification of epilepsy. Epilepsia. 2011;52(6):1052\u20137. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03041.x.","journal-title":"Epilepsia."},{"issue":"6","key":"316_CR63","first-page":"1","volume":"57","author":"R Kobau","year":"2008","unstructured":"Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, et al. Epilepsy surveillance among adults\u201319 states, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ. 2008;57(6):1\u201320.","journal-title":"MMWR Surveill Summ."},{"issue":"8","key":"316_CR64","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.116.172494","volume":"57","author":"M Brackhan","year":"2016","unstructured":"Brackhan M, Bascunana P, Postema JM, Ross TL, Bengel FM, Bankstahl M, et al. Serial quantitative TSPO-targeted PET reveals peak microglial activation up to 2 weeks after an epileptogenic brain insult. J Nucl Med. 2016;57(8):1302\u20138. https:\/\/doi.org\/10.2967\/jnumed.116.172494.","journal-title":"J Nucl Med"},{"issue":"3","key":"316_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/epi.14009","volume":"59","author":"M Brackhan","year":"2018","unstructured":"Brackhan M, Bascunana P, Ross TL, Bengel FM, Bankstahl JP, Bankstahl M. [(18) F]GE180 positron emission tomographic imaging indicates a potential double-hit insult in the intrahippocampal kainate mouse model of temporal lobe epilepsy. Epilepsia. 2018;59(3):617\u201326. https:\/\/doi.org\/10.1111\/epi.14009.","journal-title":"Epilepsia."},{"issue":"11","key":"316_CR66","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1111\/epi.16353","volume":"60","author":"P Bascunana","year":"2019","unstructured":"Bascunana P, Gendron T, Sander K, Jahreis I, Polyak A, Ross TL, et al. Ex vivo characterization of neuroinflammatory and neuroreceptor changes during epileptogenesis using candidate positron emission tomography biomarkers. Epilepsia. 2019;60(11):2325\u201333. https:\/\/doi.org\/10.1111\/epi.16353.","journal-title":"Epilepsia."},{"key":"316_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","volume":"813","author":"R Dingledine","year":"2014","unstructured":"Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol. 2014;813:109\u201322. https:\/\/doi.org\/10.1007\/978-94-017-8914-1_9.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"316_CR68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12974-016-0786-1","volume":"14","author":"KM Webster","year":"2017","unstructured":"Webster KM, Sun M, Crack P, O\u2019Brien TJ, Shultz SR, Semple BD. Inflammation in epileptogenesis after traumatic brain injury. J Neuroinflamm. 2017;14(1):10. https:\/\/doi.org\/10.1186\/s12974-016-0786-1.","journal-title":"J Neuroinflamm."},{"issue":"2","key":"316_CR69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.pbb.2012.08.025","volume":"103","author":"F Gao","year":"2012","unstructured":"Gao F, Liu Y, Li X, Wang Y, Wei D, Jiang W. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav. 2012;103(2):187\u201396. https:\/\/doi.org\/10.1016\/j.pbb.2012.08.025.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"316_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bcpt.12973","volume":"123","author":"F Gao","year":"2018","unstructured":"Gao F, Gao Y, Meng F, Yang C, Fu J, Li Y. The sphingosine 1-phosphate analogue FTY720 alleviates seizure-induced overexpression of P-glycoprotein in rat hippocampus. Basic Clin Pharmacol Toxicol. 2018;123(1):14\u201320. https:\/\/doi.org\/10.1111\/bcpt.12973.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"316_CR71","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s12035-018-1181-y","volume":"56","author":"J Pitsch","year":"2019","unstructured":"Pitsch J, Kuehn JC, Gnatkovsky V, Muller JA, van Loo KMJ, de Curtis M, et al. Anti-epileptogenic and anti-convulsive effects of fingolimod in experimental temporal lobe epilepsy. Mol Neurobiol. 2019;56(3):1825\u201340. https:\/\/doi.org\/10.1007\/s12035-018-1181-y.","journal-title":"Mol Neurobiol"},{"key":"316_CR72","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejps.2016.09.016","volume":"96","author":"M Gol","year":"2017","unstructured":"Gol M, Ghorbanian D, Hassanzadeh S, Javan M, Mirnajafi-Zadeh J, Ghasemi-Kasman M. Fingolimod enhances myelin repair of hippocampus in pentylenetetrazol-induced kindling model. Eur J Pharm Sci. 2017;96:72\u201383. https:\/\/doi.org\/10.1016\/j.ejps.2016.09.016.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"316_CR73","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s13311-017-0550-y","volume":"14","author":"A Leo","year":"2017","unstructured":"Leo A, Citraro R, Amodio N, De Sarro C, Gallo Cantafio ME, Constanti A, et al. Fingolimod exerts only temporary antiepileptogenic effects but longer-lasting positive effects on behavior in the WAG\/Rij rat absence epilepsy model. Neurotherapeutics. 2017;14(4):1134\u201347. https:\/\/doi.org\/10.1007\/s13311-017-0550-y.","journal-title":"Neurotherapeutics."},{"key":"316_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/b978-0-12-381328-2.00013-4","volume":"98","author":"MJ Novak","year":"2011","unstructured":"Novak MJ, Tabrizi SJ. Huntington\u2019s disease: clinical presentation and treatment. Int Rev Neurobiol. 2011;98:297\u2013323. https:\/\/doi.org\/10.1016\/b978-0-12-381328-2.00013-4.","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"316_CR75","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","volume":"72","author":"Group HsDCR","year":"1993","unstructured":"Group HsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 1993;72(6):971\u201383. https:\/\/doi.org\/10.1016\/0092-8674(93)90585-e.","journal-title":"Cell"},{"key":"316_CR76","first-page":"33","volume-title":"Behavioral neurobiology of Huntington\u2019s disease and Parkinson\u2019s disease","author":"HJ Waldvogel","year":"2015","unstructured":"Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel J-PG, Faull RL. The neuropathology of Huntington\u2019s disease. In: Nguyen HHP, Cenci MA, editors. Behavioral neurobiology of Huntington\u2019s disease and Parkinson\u2019s disease. Heidelberg: Springer; 2015. p. 33\u201380."},{"issue":"4","key":"316_CR77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","volume":"17","author":"KJ Wyant","year":"2017","unstructured":"Wyant KJ, Ridder AJ, Dayalu P. Huntington\u2019s disease-update on treatments. Curr Neurol Neurosci Rep. 2017;17(4):33. https:\/\/doi.org\/10.1007\/s11910-017-0739-9.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"8","key":"316_CR78","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrneurol.2015.117","volume":"11","author":"H Wood","year":"2015","unstructured":"Wood H. Neurodegenerative disease: Could fingolimod provide cognitive benefits in patients with Huntington disease? Nat Rev. 2015;11(8):426. https:\/\/doi.org\/10.1038\/nrneurol.2015.117.","journal-title":"Nat Rev"},{"issue":"9","key":"316_CR79","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"A Di Pardo","year":"2014","unstructured":"Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet. 2014;23(9):2251\u201365. https:\/\/doi.org\/10.1093\/hmg\/ddt615.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"316_CR80","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","volume":"24","author":"A Miguez","year":"2015","unstructured":"Miguez A, Garcia-Diaz Barriga G, Brito V, Straccia M, Giralt A, Gines S, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet. 2015;24(17):4958\u201370. https:\/\/doi.org\/10.1093\/hmg\/ddv218.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"316_CR81","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12017-014-8295-9","volume":"16","author":"VR Liyanage","year":"2014","unstructured":"Liyanage VR, Rastegar M. Rett syndrome and MeCP2. Neuromol Med. 2014;16(2):231\u201364. https:\/\/doi.org\/10.1007\/s12017-014-8295-9.","journal-title":"Neuromol Med."},{"issue":"9","key":"316_CR82","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/hmg\/9.9.1377","volume":"9","author":"T Bienvenu","year":"2000","unstructured":"Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, Couvert P, et al. MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet. 2000;9(9):1377\u201384. https:\/\/doi.org\/10.1093\/hmg\/9.9.1377.","journal-title":"Hum Mol Genet"},{"issue":"Pt C","key":"316_CR83","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuropharm.2013.03.024","volume":"76","author":"W Li","year":"2014","unstructured":"Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neuropharmacology. 2014;76(Pt C):737\u201346. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.024.","journal-title":"Neuropharmacology."},{"issue":"35","key":"316_CR84","doi-asserted-by":"publisher","first-page":"14230","DOI":"10.1073\/pnas.1206093109","volume":"109","author":"R Deogracias","year":"2012","unstructured":"Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA. 2012;109(35):14230\u20135. https:\/\/doi.org\/10.1073\/pnas.1206093109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"S2","key":"316_CR85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1684\/epd.2016.0844","volume":"18","author":"DA Nita","year":"2016","unstructured":"Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(S2):73\u201388. https:\/\/doi.org\/10.1684\/epd.2016.0844.","journal-title":"Epileptic Disord."},{"key":"316_CR86","unstructured":"Mole SE, Williams RE. Neuronal Ceroid-Lipofuscinoses. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K et al, editors. GeneReviews((R)). Seattle; 1993."},{"issue":"10 Pt B","key":"316_CR87","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.bbadis.2015.05.014","volume":"1852","author":"JD Cooper","year":"2015","unstructured":"Cooper JD, Tarczyluk MA, Nelvagal HR. Towards a new understanding of NCL pathogenesis. Biochim Biophys Acta. 2015;1852(10 Pt B):2256\u201361. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.014.","journal-title":"Biochim Biophys Acta."},{"key":"316_CR88","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/b978-0-444-59565-2.00038-1","volume":"113","author":"B Chabrol","year":"2013","unstructured":"Chabrol B, Caillaud C, Minassian B. Neuronal ceroid lipofuscinoses. Handb Clin Neurol. 2013;113:1701\u20136. https:\/\/doi.org\/10.1016\/b978-0-444-59565-2.00038-1.","journal-title":"Handb Clin Neurol."},{"issue":"8","key":"316_CR89","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.ymthe.2017.04.021","volume":"25","author":"J Groh","year":"2017","unstructured":"Groh J, Berve K, Martini R. Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis. Mol Ther. 2017;25(8):1889\u201399. https:\/\/doi.org\/10.1016\/j.ymthe.2017.04.021.","journal-title":"Mol Ther"},{"issue":"10023","key":"316_CR90","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/s0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(15)01314-8.","journal-title":"Lancet"},{"issue":"6","key":"316_CR91","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356. https:\/\/doi.org\/10.1016\/s1474-4422(14)70049-3.","journal-title":"Lancet Neurol."},{"issue":"15","key":"316_CR92","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/wnl.0000000000001462","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, O\u2019Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582\u201391. https:\/\/doi.org\/10.1212\/wnl.0000000000001462.","journal-title":"Neurology."},{"key":"316_CR93","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3389\/fphar.2019.00807","volume":"10","author":"S Grassi","year":"2019","unstructured":"Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, et al. Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases. Front Pharmacol. 2019;10:807. https:\/\/doi.org\/10.3389\/fphar.2019.00807.","journal-title":"Front Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00316-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00316-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00316-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T12:36:33Z","timestamp":1696422993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00316-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["316"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00316-1","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"22 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Pablo Bascu\u00f1ana, Luisa M\u00f6hle, Mirjam Brackhan, and Jens Pahnke have no conflicts of interest that are directly relevant to the content of this review\/study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}